Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

• Johnson & Johnson is currently trading at $266.81, which is below the consensus price target of $272.82, suggesting potential upside as analysts maintain a Moderate Buy rating based on recent performance.
• The company recently reported that its RYBREVANT (amivantamab) plus chemotherapy regimen achieved a median overall survival of 34.3 months in EGFR exon 20 insertion mutation-positive non-small cell lung cancer, marking the longest reported survival in this patient population and strengthening its oncology portfolio.
• Johnson & Johnson has raised its 2026 outlook to 6.5% adjusted operational sales growth and 7.3% adjusted earnings-per-share growth, with total revenue expected to exceed $100 billion for the first time, driven by strong performance in the first two quarters of the year.
• Executives have indicated a clear line of sight to double-digit growth by the end of the decade, supported by a robust pipeline including 12 molecules in Phase III development and recent acquisitions like Halda Therapeutics and Firefly Bio that expand capabilities in oncology and immunology.
• The stock offers a dividend yield of 2.02%, providing income stability for investors, while the company’s low beta of 0.24 indicates lower volatility compared to the broader market, making it a defensive holding in uncertain economic conditions.